Showing paper detailed information
Citation Information
Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1374-82. doi: 10.1158/1055-9965.EPI-12-1424. Epub 2013 Jun 7.
Plasma sphingolipids and lung cancer: a population-based, nested case-control study.
Alberg AJ, Armeson K, Pierce JS, Bielawski J, Bielawska A, Visvanathan K, Hill EG, Ogretmen B.
Analytical methods | ||
|---|---|---|
| Comparative study | #1 | |
| Chromatography | LC | |
| Ion source | ESI | |
| Positive/Negative mode | – | |
| Mass analyzer | – | |
| Identification level | MS/MS | |
Sample information | ||
|---|---|---|
| Comparative study | #1 | |
| Country | US | |
| Specimen | plasma | |
| Marker function | prediagnosis | |
| Participants(Case) | Cancer type | lung cancer |
| Stage | – | |
| Number | 100 | |
| Gender (M,F) | 54, 46 | |
| Mean age (range) (M,F) | 63.9 | |
| Smoking status | former, current, non-smoker | |
| Participants(Control) | Type | healthy |
| Number | 200 | |
| Gender (M,F) | 108, 92 | |
| Mean age (range) (M,F) | 63.7 | |
| Smoking status | former, current, non-smoker | |
Data processing and metabolite identification | |
|---|---|
| Data processing software | – |
| Database search | – |
Statistical analysis | |
|---|---|
| Differential analysis method | – |
| Classification method | – |
| Survival analysis method | – |
Lung cancer-related metabolites identified in the paper
| Metabolite | Author-emphasized biomarkers | Mean concentration (case) | Mean concentration (control) | Fold change (case/control) | P-value | FDR | VIP |
|---|---|---|---|---|---|---|---|
| dihydrosphingosine | – | 0.022 uM | 0.022 uM | 1.00 | 0.84 | – | – |
| sphingosine | – | 0.031 uM | 0.03 uM | 1.03 | 0.22 | – | – |
| C20:1-ceramide | – | 0.035 uM | 0.033 uM | 1.06 | 0.17 | – | – |
| C18:1-ceramide | – | 0.046 uM | 0.043 uM | 1.07 | 0.04 | – | – |
| dihydroC16-ceramide | – | 0.049 uM | 0.047 uM | 1.04 | 0.32 | – | – |
| C26:1-ceramide | – | 0.054 uM | 0.052 uM | 1.04 | 0.12 | – | – |
| C14-ceramide | – | 0.064 uM | 0.066 uM | 0.97 | 0.16 | – | – |
| C22:1-ceramide | – | 0.1 uM | 0.096 uM | 1.04 | 0.05 | – | – |
| C26-ceramide | – | 0.101 uM | 0.096 uM | 1.05 | 0.05 | – | – |
| dihydroS1P | – | 0.11 uM | 0.11 uM | 1.00 | 0.12 | – | – |
| C18-ceramide | – | 0.15 uM | 0.15 uM | 1.00 | 0.29 | – | – |
| C22-ceramide | – | 0.36 uM | 0.35 uM | 1.03 | 0.07 | – | – |
| C20-ceramide | – | 0.4 uM | 0.37 uM | 1.08 | 0.06 | – | – |
| C16-ceramide | – | 0.43 uM | 0.41 uM | 1.05 | 0.14 | – | – |
| sphingosine 1-phosphate | V | 0.78 uM | 0.75 uM | 1.04 | 0.10 | – | – |
| C24:1-ceramide | – | 1 uM | 0.96 uM | 1.04 | 0.07 | – | – |
| C24-ceramide | – | 2.64 uM | 2.48 uM | 1.06 | 0.02 | – | – |
| total ceramides | – | 5.48 uM | 5.21 uM | 1.05 | 0.02 | – | – |
| Metabolite | Author-emphasized biomarkers | Cutoff value | AUROC (95%CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
|---|---|---|---|---|---|---|
| dihydrosphingosine | – | – | – | – | – | – |
| sphingosine | – | – | – | – | – | – |
| C20:1-ceramide | – | – | – | – | – | – |
| C18:1-ceramide | – | – | – | – | – | – |
| dihydroC16-ceramide | – | – | – | – | – | – |
| C26:1-ceramide | – | – | – | – | – | – |
| C14-ceramide | – | – | – | – | – | – |
| C22:1-ceramide | – | – | – | – | – | – |
| C26-ceramide | – | – | – | – | – | – |
| dihydroS1P | – | – | – | – | – | – |
| C18-ceramide | – | – | – | – | – | – |
| C22-ceramide | – | – | – | – | – | – |
| C20-ceramide | – | – | – | – | – | – |
| C16-ceramide | – | – | – | – | – | – |
| sphingosine 1-phosphate | V | – | – | – | – | – |
| C24:1-ceramide | – | – | – | – | – | – |
| C24-ceramide | – | – | – | – | – | – |
| total ceramides | – | – | – | – | – | – |
Paper graphical summary
